États-Unis · Agences & temps réel · PR Newswire

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

Publié par PR Newswire · États-Unis il y a 1 h

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

À lire aussi

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

Partager

À lire aussi

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows